Mark Espeland to Neuropsychological Tests
This is a "connection" page, showing publications Mark Espeland has written about Neuropsychological Tests.
Connection Strength
1.132
-
Espeland MA, Rapp SR, Manson JE, Goveas JS, Shumaker SA, Hayden KM, Weitlauf JC, Gaussoin SA, Baker LD, Padula CB, Hou L, Resnick SM. Long-term Effects on Cognitive Trajectories of Postmenopausal Hormone Therapy in Two Age Groups. J Gerontol A Biol Sci Med Sci. 2017 Jun 01; 72(6):838-845.
Score: 0.132
-
Espeland MA, Lipska K, Miller ME, Rushing J, Cohen RA, Verghese J, McDermott MM, King AC, Strotmeyer ES, Blair SN, Pahor M, Reid K, Demons J, Kritchevsky SB. Effects of Physical Activity Intervention on Physical and Cognitive Function in Sedentary Adults With and Without Diabetes. J Gerontol A Biol Sci Med Sci. 2017 Jun 01; 72(6):861-866.
Score: 0.132
-
Padula CB, Weitlauf JC, Rosen AC, Reiber G, Cochrane BB, Naughton MJ, Li W, Rissling M, Yaffe K, Hunt JR, Stefanick ML, Goldstein MK, Espeland MA. Longitudinal Cognitive Trajectories of Women Veterans from the Women's Health Initiative Memory Study. Gerontologist. 2016 Feb; 56(1):115-25.
Score: 0.119
-
Vaughan L, Bushnell C, Bell CL, Espeland MA. Global cognitive function before, surrounding, and after ischemic stroke: the role of risk and protective factors varies with time among ischemic stroke survivors. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2016; 23(1):117-31.
Score: 0.115
-
Klepin HD, Geiger AM, Bandos H, Costantino JP, Rapp SR, Sink KM, Lawrence JA, Atkinson HH, Espeland MA. Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. Cancer Prev Res (Phila). 2014 Jan; 7(1):161-8.
Score: 0.103
-
Rapp SR, Legault C, Espeland MA, Resnick SM, Hogan PE, Coker LH, Dailey M, Shumaker SA. Validation of a cognitive assessment battery administered over the telephone. J Am Geriatr Soc. 2012 Sep; 60(9):1616-23.
Score: 0.095
-
Espeland MA, Shumaker SA, Limacher M, Rapp SR, Bevers TB, Barad DH, Coker LH, Gaussoin SA, Stefanick ML, Lane DS, Maki PM, Resnick SM. Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition. J Womens Health (Larchmt). 2010 Mar; 19(3):371-9.
Score: 0.080
-
Espeland MA, Tindle HA, Bushnell CA, Jaramillo SA, Kuller LH, Margolis KL, Mysiw WJ, Maldjian JA, Melhem ER, Resnick SM. Brain volumes, cognitive impairment, and conjugated equine estrogens. J Gerontol A Biol Sci Med Sci. 2009 Dec; 64(12):1243-50.
Score: 0.077
-
Espeland MA, Coker LH, Wallace R, Rapp SR, Resnick SM, Limacher M, Powell LH, Messina CR. Association between alcohol intake and domain-specific cognitive function in older women. Neuroepidemiology. 2006; 27(1):1-12.
Score: 0.061
-
Baker LD, Rapp SR, Shumaker SA, Manson JE, Sesso HD, Gaussoin SA, Harris D, Caudle B, Pleasants D, Espeland MA. Design and baseline characteristics of the cocoa supplement and multivitamin outcomes study for the Mind: COSMOS-Mind. Contemp Clin Trials. 2019 08; 83:57-63.
Score: 0.038
-
Sink KM, Espeland MA, Rushing J, Castro CM, Church TS, Cohen R, Gill TM, Henkin L, Jennings JM, Kerwin DR, Manini TM, Myers V, Pahor M, Reid KF, Woolard N, Rapp SR, Williamson JD. The LIFE Cognition Study: design and baseline characteristics. Clin Interv Aging. 2014; 9:1425-36.
Score: 0.027
-
Davenport EM, Whitlow CT, Urban JE, Espeland MA, Jung Y, Rosenbaum DA, Gioia GA, Powers AK, Stitzel JD, Maldjian JA. Abnormal white matter integrity related to head impact exposure in a season of high school varsity football. J Neurotrauma. 2014 Oct 01; 31(19):1617-24.
Score: 0.027
-
Ammann EM, Pottala JV, Harris WS, Espeland MA, Wallace R, Denburg NL, Carnahan RM, Robinson JG. ?-3 fatty acids and domain-specific cognitive aging: secondary analyses of data from WHISCA. Neurology. 2013 Oct 22; 81(17):1484-91.
Score: 0.026
-
Kerwin DR, Zhang Y, Kotchen JM, Espeland MA, Van Horn L, McTigue KM, Robinson JG, Powell L, Kooperberg C, Coker LH, Hoffmann R. The cross-sectional relationship between body mass index, waist-hip ratio, and cognitive performance in postmenopausal women enrolled in the Women's Health Initiative. J Am Geriatr Soc. 2010 Aug; 58(8):1427-32.
Score: 0.020
-
Tooze JA, Gaussoin SA, Resnick SM, Fischbein NJ, Robinson JG, Bryan RN, An Y, Espeland MA. A uniform approach to modeling risk factor relationships for ischemic lesion prevalence and extent: the Women's Health Initiative Magnetic Resonance Imaging study. Neuroepidemiology. 2010; 34(1):55-62.
Score: 0.020
-
Williamson JD, Espeland M, Kritchevsky SB, Newman AB, King AC, Pahor M, Guralnik JM, Pruitt LA, Miller ME. Changes in cognitive function in a randomized trial of physical activity: results of the lifestyle interventions and independence for elders pilot study. J Gerontol A Biol Sci Med Sci. 2009 Jun; 64(6):688-94.
Score: 0.019
-
Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK, Shumaker SA. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab. 2006 May; 91(5):1802-10.
Score: 0.015
-
Resnick SM, Coker LH, Maki PM, Rapp SR, Espeland MA, Shumaker SA. The Women's Health Initiative Study of Cognitive Aging (WHISCA): a randomized clinical trial of the effects of hormone therapy on age-associated cognitive decline. Clin Trials. 2004; 1(5):440-50.
Score: 0.013
-
Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May 28; 289(20):2663-72.
Score: 0.012